Cancer Pain

Cancer Pain is a subgroup of the MASCC Palliative Care Study Group

Mellar Davis, MD
Akhila Reddy, MD

>> How to Join
To join a Study Group, login to your account, and click the Manage My Account/Profile.  Scroll down to your profile data and select "Edit". Then select the study group as one of your three Study Group selections. Click SAVE.

To join a Subgroup, you must be a member of the parent Study Group. Login to your account, and click Manage My Account/Profile.  Scroll down to your profile data and select "Edit". Then select the subgroup. Click SAVE.
Subgroups do not count toward your three Study Group selections.
>> More information or to contact Study Group/Subgroup leadership
To contact a Study Group or Subgroup Leader, search for their name in the member directory.
For more information or questions, contact the MASCC office at [email protected].

Mission and Goals

More than 80% of patients with advanced cancer develop severe pain, a primary concern for both patients and their caretakers. For these patients, opioids are a highly effective treatment that can reduce pain intensity, restore function, and improve quality of life. However, the drug, dosage, and route of administration are complex and must be personalized for maximum symptom control. In addition, addiction risk, overdose, drug interactions, opioid availability in developing countries, and the high cost of these drugs are critical issues in the use of opioids for cancer pain. The Subgroup has been established to focus attention on these issues and to address some of the most challenging issues in cancer pain management. Topics of interest include the following:

• Opioid Choices: First- and second-line opioids used in cancer pain management
• Opioid dosing strategies in acute and chronic pain management
• Opioid availability: advocate for the availability of opioid analgesics in developing countries
• Patient and caregiver perspectives on NARCAN® (naloxone HCl) spray for accidental opioid overdose and the impact of provider education on its prescription in high-risk patients
• Development of guidelines to address non-medical opioid use among cancer patients
• Buprenorphine as a means of tapering opioids in patients with prolonged abstinence and complex persistent dependence

 Subgroup Activities
Subgroup News
Subgroup Annual Report


Last Updated on Wednesday, April 20, 2022 09:05 AM